Publications by authors named "A Lugaresi"
Background: Hypogammaglobulinemia (HG) is a known side effect of treatment with anti-CD20 monoclonal antibodies, and it is associated with the risk of infections.
Objectives: Aim of this retrospective multicentre study was to assess the frequency of HG in Multiple Sclerosis (MS) and Neuromyelitis Optica Spectrum Disorder patients treated with Ocrelizumab or Rituximab and its association with the occurrence of severe infections (SI). Furthermore, predictors of HG and SI were sought.
'Active' and 'non-active' secondary progressive MS (SPMS) have distinct pathophysiological mechanisms and clinical characteristics, but there is still no consensus regarding the frequency of these MS forms in the real-world setting. We aimed to evaluate the frequency of 'active' and 'non-active' SPMS in a large cohort of Italian MS patients and the differences in terms of clinical and MRI characteristics and disease progression. This multicenter study collected data about MS patients who have transitioned to the SP form in the period between 1st January 2014 and 31st December 2019 and followed by the MS centers contributing to the Italian MS Registry.
View Article and Find Full Text PDFArticle Synopsis
- The study compares disability progression in Multiple Sclerosis (MS) patients based on age of onset: pediatric (POMS), adult (AOMS), and late-onset (LOMS), as well as those with and without progression independent of relapse activity (PIRA).
- Data from 3,777 MS patients revealed that AOMS showed significant disability increases compared to POMS starting in the second year, with POMS having a less steep disability trajectory over time.
- The findings underscore that younger patients with MS experience different disability progression patterns than older patients, highlighting the importance of age in MS disease management.
Article Synopsis
- * Machine learning models were applied to predict confirmed disability progression after two years, achieving a ROC-AUC score of 0.71, indicating moderate accuracy, while historical disability was found to be a stronger predictor than treatment or relapse history.
- * The research followed strict guidelines and made its coding accessible for others to facilitate future benchmarking in predicting disability progression in MS patients.